Meeting
2019 Genitourinary Cancers Symposium
Radium 223 treatment in metastatic castrate-resistant prostate cancer: Impact of sequencing on survival—Real-world outcomes from a single UK centre.
Authors
Xue Yan Jiang
Northern Centre for Cancer Care (NCCC), Freeman Hospital, Newcastle, United Kingdom
Xue Yan Jiang , Sarah Atkinson , Sam Cuming , Alexander Burns , Rachel Anne Pearson , John A. Frew , Ashraf S. Azzabi , Rhona Margaret McMenemin , Ian David Pedley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 223)
DOI
10.1200/JCO.2019.37.7_suppl.223
Abstract #
223
Poster Bd #
K2
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience.
First Author: Niamh Peters
Poster
2018 Genitourinary Cancers Symposium
Primary resistance in docetaxel and androgen deprivation therapy in metastatic castrate sensitive prostate cancer patients.
First Author: Athanasios Pouptsis
Poster
2018 Genitourinary Cancers Symposium
Patterns of progression in bone and soft tissue following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC).
First Author: Megan Ann McNamara
Poster
2016 Genitourinary Cancers Symposium
Imaging response during therapy (tx) with radium-223 (Ra-223) for castrate resistant prostate cancer (CRPC) with bone metastases (BM).
First Author: Daniel Keizman